Roche: What we learnt from our day with the CFO in Paris
NEUTRAL, Fair Value CHF236 (+2%)
Interestingly, the CFO Alan Hippe spent most of his time answering questions about products in the Pharmaceuticals division and issues about products in the Diagnostics division. Few were finance-related actually which is a good reflection of what Roche is about. And he was strongly confident about both the HER2+ and rituximab franchises and globally about the pipeline. He was more cautious about the opportunity for deep margin expansion because they are already high, as the group is lean and efficient on many fronts and as some new products can carry higher costs. By the end, the tone was positive and the speech well received.
Full report available to subscribers
Please contact firstname.lastname@example.org